文献速递血栓与止血贫血与红细胞疾病

泊马度胺治疗遗传性出血性毛细血管扩张症的长期随访研究

Pomalidomide for hereditary hemorrhagic telangiectasia: after trial longitudinal assessment study (PATH-HHT ATLAS).
PubMed 文献 · Blood Adv · 2026-01-01

结果显示鼻出血严重度评分和血液学支持评分持续改善,但对消化道出血效果较差,半数患者因中性粒细胞减少减量后多数仍维持疗效。

要点

  • 泊马度胺可长期改善 HHT 相关鼻出血严重度评分。
  • 对消化道出血效果较差,尤其在高红细胞输注需求患者。
  • 50% 患者因中性粒细胞减少减量,多数减量后仍有效。

核心结论

  • 泊马度胺对 HHT 相关鼻出血在延长治疗期间有效,但存在不可忽视的潜在毒性,可考虑用于特定 HHT 患者。

主要发现

  • 平均鼻出血严重度评分从基线 5.55 分降至第 12 个月 2.80 分(P< .0001)。
  • 平均血液学支持评分从治疗前 6 个月 9.11 个红细胞单位当量(RUEs)降至第 7-12 个月 5.73 RUEs(P = .0056)。
  • 泊马度胺对消化道出血效果不及鼻出血,尤其在高红细胞输注需求患者中。
  • 共 105.2 患者年泊马度胺治疗中,0 例发生周围神经病变,1 例发生静脉血栓栓塞,5 例发生严重感染。

临床怎么用

  • 泊马度胺可用于特定 HHT 患者的长期治疗,需密切监测中性粒细胞减少等毒性。
  • 对高红细胞输注需求的 HHT 消化道出血患者,泊马度胺疗效有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hereditary hemorrhagic telangiectasia (HHT) causes severe recurrent epistaxis, chronic gastrointestinal bleeding, solid organ arteriovenous malformations, and significant anemia. Although it is the second most common inherited bleeding disorder worldwide, no approved therapies exist. The multicenter, US randomized, controlled PATH-HHT trial demonstrated efficacy of short-term pomalidomide treatment of epistaxis in HHT. However, questions regarding long-term safety, effectiveness, and utility for HHT-associated gastrointestinal bleeding remain. The PATH-HHT ATLAS (after trial longitudinal assessment study) was a multicenter US longitudinal observational study evaluating patients enrolled in PATH-HHT who continued pomalidomide after PATH-HHT through a poststudy drug access program, with ongoing close monitoring per PATH-HHT protocol and as mandated by the US Food and Drug Administration. Sixty-two patients treated with pomalidomide for HHT for up to 4.4 years were included. Significant, durable improvements in mean epistaxis severity score (5.55 points [baseline] to 2.80 points [month 12]; P< .0001) and mean hematologic support score (9.11 red cell unit equivalents [RUEs] during 6 months pretreatment to 5.73 RUEs [months 7-12]; P = .0056) were observed. Pomalidomide was less effective for gastrointestinal bleeding than for epistaxis, particularly in patients with high red blood cell transfusion requirements. Thirty-one patients (50%) underwent dose reduction from 4 mg daily, primarily due to neutropenia, but most maintained effectiveness at 2 or 3 mg daily. Over 105.2 patient-years of pomalidomide treatment, 0 patients developed peripheral neuropathy, 1 developed venous thromboembolism, and 5 developed serious infections. In conclusion, pomalidomide was effective for HHT-associated epistaxis over extended durations, albeit with nontrivial potential toxicities, and may be considered for certain patients with HHT. This trial was registered at www.clinicaltrials.gov as NCT07018401.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zhang E, Kasthuri RS, Parambil J, et al. Pomalidomide for hereditary hemorrhagic telangiectasia: after trial longitudinal assessment study (PATH-HHT ATLAS). Blood Adv. 2026. PMID: 41512167. doi:10.1182/bloodadvances.2025018382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。